Becton Dickinson

Fairview Health Services has become the first US health system to put the BD Vmax 160 pharmacy automation robot into operation. The system automates storage, tracking and picking, particularly for specialty therapies and temperature-controlled medications, and is designed for temperatures of 2–8 °C. The BD Vmax 160 offers automatic replenishment with BD EasyLoad (three seconds loading time per container, 99.8% accuracy), automated labeling for all 50 US states and expiration-date recognition to prevent dispensing expired products. The implementation complements BD’s existing pharmacy automation solutions and the Incada Connected Care Platform. » More on de.investing.com

Becton Dickinson’s stock reached $187.50, marking a 52-week high after gaining 19.65% year-to-date. In the third fiscal quarter the company beat analysts’ expectations with adjusted earnings of $3.23 per share and revenue of $5.0 billion. Becton Dickinson subsequently raised its full-year guidance; InvestingPro also notes the dividend has been increased every year for 55 years. » More on de.investing.com

BD appoints Gary Sorsher, effective September 8, as executive vice president and chief quality officer. Sorsher has more than 30 years of experience in senior quality roles and was most recently chief quality officer at Edwards Lifesciences. At the same time, Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with the company (joined 1998). BD emphasizes the importance of quality for customer and patient trust; the company operates globally in medical technology, biopharma systems and interventional therapies. » More on de.investing.com

BD has completed recruitment of 477 patients at 32 sites in the US and Europe for the randomized PREVENT study of the resorbable Phasix Mesh. The study examines prophylactic reinforcement to prevent incisional hernias after open midline abdominal surgeries in high‑risk patients and is the first larger randomized trial for this indication. Patients will be followed for 24 months to the primary endpoint; an extension to five years to assess safety and clinical data is planned. BD intends to use the study data to support a planned submission to the US FDA. » More on de.investing.com

Becton Dickinson reported adjusted EPS of $3.23 for Q3 (expectation $3.13) and revenue of $5.0 billion (expectation $4.89 billion). The company raised its revenue expectation for 2026 to the upper end of the targeted low double-digit growth rate and confirmed an adjusted EPS range of $12.62–$12.72. Margins were under pressure from tariffs (about 110 basis points) but were partially offset by productivity gains; free cash flow year-to-date was $1.7 billion. » More on de.investing.com